Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters (scientific article published in September 2005)

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes

Q27619756

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Q27641252

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Q27642450

Coronavirus as a possible cause of severe acute respiratory syndrome

Q28200848

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

Q28202401

In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease

Q28343611

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements

Q28373315

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Q29615907

A novel coronavirus associated with severe acute respiratory syndrome

Q29617553

The Genome sequence of the SARS-associated coronavirus

Q29619007

Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV.

Q33206632

Viral proteinases

Q34164183

Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase

Q34270281

Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site.

Q34328765

Small molecules targeting severe acute respiratory syndrome human coronavirus

Q35970698

Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity

Q37480211

Picornavirus protein processing--enzymes, substrates, and genetic regulation

Q37892782

Viral proteinases: weakness in strength

Q38138706

Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines

Q41579098

Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection

Q42600546

Rapid diversity-oriented synthesis in microtiter plates for in situ screening: discovery of potent and selective alpha-fucosidase inhibitors.

Q44610505

3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism

Q44839752

Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro.

Q44861300

Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate

Q44899503

Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points

Q44904083

Discovery of picomolar slow tight-binding inhibitors of alpha-fucosidase

Q45067883

High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase

Q45110672

Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of the octapeptide

Q45121648

Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro

Q45164294

Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics.

Q47924234

Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS.

Q51661127

P433

issue

P407

language of work or name

English

Q1860

P304

page(s)

5240-5252

P577

publication date

2005-09-01

P1433

published in

Bioorganic & Medicinal Chemistry

Q2904200

P1476

title

Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters

P478

volume

Reverse relations

cites work (P2860)

Q35923992	An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.
Q34332580	Antiviral drugs specific for coronaviruses in preclinical development
Q99237635	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?
Q45227423	Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase
Q95601929	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
Q96431581	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
Q36534375	Coronaviruses and their therapy
Q27683531	Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases
Q39967863	Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents.
Q46711512	Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease
Q93180376	Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics
Q34849521	Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
Q38135197	From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses
Q45253334	From the similarity analysis of protein cavities to the functional classification of protein families using cavbase
Q40068309	Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors.
Q90670384	Improved synthesis of rupintrivir
Q83232837	Individual and common inhibitors of coronavirus and picornavirus main proteases
Q36943869	Long-range cooperative interactions modulate dimerization in SARS 3CLpro.
Q43094227	Mechanistic study of the reaction of thiol-containing enzymes with alpha,beta-unsaturated carbonyl substrates by computation and chemoassays
Q35620215	New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors
Q27671833	Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease
Q93190302	Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19
Q37658853	Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitors
Q36403490	Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study
Q36441511	Potential antivirals and antiviral strategies against SARS coronavirus infections
Q37283689	Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy.
Q93263973	Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study
Q34218166	Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery
Q39727842	Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
Q89477874	Recent discovery and development of inhibitors targeting coronaviruses
Q26753001	Roles of the Picornaviral 3C Proteinase in the Viral Life Cycle and Host Cells
Q91908893	Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)
Q27653428	Structural Basis of Inhibition Specificities of 3C and 3C-like Proteases by Zinc-coordinating and Peptidomimetic Compounds
Q80849382	Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors
Q27648126	Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors
Q42858751	Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors
Q43056416	Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease
Q88187367	Techniques used for the discovery of therapeutic compounds: The case of SARS
Q98563452	The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020
Q36923117	The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease